Evidence map›Paper›PMID 40964365›Full record

ArticlebioRxiv : the preprint server for biology2025

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

Muhannad Abu-Remaileh, Laura A Stransky, Nikita Bhalerao, Nitin H Shirole, Qinqin Jiang, Eddy Saad, Marc Machaalani, Sean M Vigeant, Hilina Woldemichael, Charles Xu and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Muhannad Abu-RemailehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-4962-3826
Laura A StranskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-8834-936X
Nikita BhaleraoDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0009-0007-1633-4389
Nitin H ShiroleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-2579-456X
Qinqin JiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Eddy SaadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-8700-9312
Marc MachaalaniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-6708-9922
Sean M VigeantDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Hilina WoldemichaelBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, USA.
Charles XuBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, USA.
Jing LuNiKang Therapeutics 200 Powder Mill Rd E500, Wilmington, DE 19803, USA.
Hairong WeiNiKang Therapeutics 200 Powder Mill Rd E500, Wilmington, DE 19803, USA.
Zhihong LiuNiKang Therapeutics 200 Powder Mill Rd E500, Wilmington, DE 19803, USA.
William SunNiKang Therapeutics 200 Powder Mill Rd E500, Wilmington, DE 19803, USA.
Kei EnomotoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-6210-8699
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-9201-3217
Jason R PitarresiDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0001-9549-4768
Steven A CarrBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, USA.ORCID 0000-0002-7203-4299
Namrata D UdeshiBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, USA.ORCID 0000-0001-5312-1402
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-0574-4856

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8M
Center of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3M
Proteogenomic Predictors of Recurrence in Non-small Cell Lung CancerU01CA271402 · NCI · WASHINGTON UNIVERSITY · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.0M
Role of Peripheral Insulin Resistance and Inflammation in Alzheimer’s DiseaseR01AG085308 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JASON K KIM · 2024 to 2026
$2.2M
Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver DiseaseR01DK133772 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JASON K KIM · 2023 to 2026
$1.9M
NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R35 CA210068NCI NIH HHS U01 CA271402NCI NIH HHS U24 CA270823NIA NIH HHS R01 AG085308NIDDK NIH HHS R01 DK133772
6 · The paper itself

Abstract

Kidney cancer frequently causes paraneoplastic syndromes, including hypercalcemia and cachexia, but the underlying mechanisms are incompletely understood. The most common form of kidney cancer, clear cell renal cell carcinoma, is frequently caused by loss of the pVHL tumor suppressor protein and the resulting upregulation of the HIF2 transcription factor. We show that

Identifiers

PMID40964365
PMCPMC12439952

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.